Sponsored genetic testing programs can run afoul of federal laws, including the FCA and AKS, if not designed correctly.

New treatment paradigms are making biopharma industry stakeholder communications more ambitious and complex. But they must ...

Oxygen, crucial for cellular respiration, is affected by pressure variations within a bioreactor, with higher pressure at the bottom leading to increased oxygen solubility. This heterogeneity is ...

In this episode, Host Erin Harris sits down with Dr. Simrit Parmar, Founder of Cellenkos, to explore how the company is pioneering umbilical cord blood-derived Regulatory T cell (Treg) cell therapies ...

Tom Chalberg, Ph.D., co-founder of Genascence, explains how gene therapies are moving beyond the confines of rare diseases and into a wider range of indications.

Given the near-constant technological advancements in AI, potential AI policy updates, and regulatory changes, flexible AI ...

In the dynamic pharmaceutical industry, successful product launches are critical to business success. For small and midsized biotech firms, where the reliance on a few key assets is high, the stakes ...

Should aspiring biopharmaceutical leaders focus on deep specialization and expertise in a singular area, or seek new and variable experiences across different parts of the business, developing a ...

Over the last 15 years, biopharmaceutical compliance departments, and chief compliance officers, have been better resourced, with more direct reporting lines to company leadership, than ever before. A ...